Ariad's offering with over-allotment raises $258M to advance ponatinib
This article was originally published in Scrip
Executive Summary
Ariad Pharmaceuticals initially raised $224 million through the sale of 21.5 million shares at $10.42 in a follow-on offering. On 16 December, it said that the underwriters exercised their over-allotment option, resulting in the issuance of 24.7 million shares, for total gross proceeds of about $258 million.